INTERNATIONAL PATENT: NATIONAL CANCER CENTER, 국립암센터 FILES APPLICATION FOR "TLK BIOMARKER COMPOSITION FOR PREDICTING PARP INHIBITOR TREATMENT RESPONSIVENESS OR PROGNOSIS OF BRCA MUTANT CANCER PATIENTS AND USE THEREOF"

GENEVA, Sept. 9 -- NATIONAL CANCER CENTER (323, llsan-ro,Ilsandong-gu, Goyang-siGyeonggi-do 10408), 국립암센터 (경기도고양시 일산동구일산로 323) filed a patent application (PCT/KR2025/001979) for "TLK BIOMARKER COMPOSITION FOR PREDICTING PARP INHIBITOR TREATMENT RESPONSIVENESS OR PROGNOSIS OF BRCA MUTANT CANCER PATIENTS AND USE THEREOF" on Feb 11, 2025. With publication no. WO/2025/183387, the details related to the patent application was published on Sep 04, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization ...